Shedding of infectious SARS-CoV-2 despite vaccination
暂无分享,去创建一个
D. O’Connor | Y. Kawaoka | T. Friedrich | J. C. Eickhoff | P. Halfmann | N. Wilson | R. Westergaard | H. Segaloff | A. Bateman | A. Kocharian | A. Kita-Yarbro | K. Riemersma | L. A. Haddock | K. Florek | Nick Minor | Katarina M Grande | Brittany Grogan | Gunnar E. Jeppson | Jens C. Eickhoff
[1] Cory C. Funk,et al. Risk factors for severe COVID-19 differ by age for hospitalized adults , 2022, Scientific Reports.
[2] D. McManus,et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness , 2022, Nature Microbiology.
[3] S. Crovella,et al. Comparison between nucleic acid amplification tests, antigen immunofluorescence assay, and in vitro infectivity in SARS-CoV-2 diagnosis , 2022, Brazilian Journal of Microbiology.
[4] N. Peek,et al. Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors , 2022, Diabetes Therapy.
[5] J. McLaughlin,et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study , 2022, The Lancet Respiratory Medicine.
[6] M. Sughayer,et al. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies , 2022, Vaccine.
[7] S. Doron,et al. Cycle threshold values and SARS‐CoV‐2: Relationship to demographic characteristics and disease severity , 2022, Journal of medical virology.
[8] F. Meloni,et al. Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination , 2022, Vaccines.
[9] A. Riva,et al. Low‐frequency variants in mildly symptomatic vaccine breakthrough infections presents a doubled‐edged sword , 2022, Journal of medical virology.
[10] S. Cramer,et al. Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults , 2022, medRxiv.
[11] M. Exline,et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study , 2022, BMJ.
[12] C. Lambert,et al. Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers , 2022, Frontiers in Immunology.
[13] K. Nilgiriwala,et al. Impact of Delta and Vaccination on SARS-CoV-2 transmission risk: Lessons for Emerging Breakthrough infections , 2022, medRxiv.
[14] R. Irizarry,et al. Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico , 2022, The Lancet Regional Health - Americas.
[15] B. Nunes,et al. Comparative complete scheme and booster effectiveness of COVID‐19 vaccines in preventing SARS‐CoV‐2 infections with SARS‐CoV‐2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case–case study based on electronic health records , 2022, medRxiv.
[16] J. Kim,et al. The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data , 2022, Vaccines.
[17] M. Dimopoulos,et al. Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222 , 2022, Biomedicines.
[18] S. Zeger,et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.
[19] D. Zeng,et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina , 2022, The New England journal of medicine.
[20] G. Alter,et al. Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children , 2022, medRxiv.
[21] T. Peto,et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants , 2022, The New England journal of medicine.
[22] S. Haneuse,et al. Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections , 2021, JCI insight.
[23] S. Kissler,et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons , 2021, The New England journal of medicine.
[24] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.
[25] A. Fasano,et al. Virologic features of SARS-CoV-2 infection in children. , 2021, The Journal of infectious diseases.
[26] I. Diamond,et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, Nature Medicine.
[27] T. Peto,et al. The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission , 2021, medRxiv.
[28] M. Holodniy,et al. COVID-19 Vaccine Breakthrough Infections in the Veterans Health Administration. , 2021, medRxiv.
[29] Michael I. Mandel,et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.
[30] O. Mor,et al. Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[31] I. Diamond,et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, medRxiv.
[32] Catherine M. Brown,et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[33] V. Lee,et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study , 2021, Clinical Microbiology and Infection.
[34] M. Lipsitch,et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.
[35] M. Churpek,et al. The impact of vaccination to control COVID-19 burden in the United States: A simulation modeling approach , 2021, PloS one.
[36] F. Rey,et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.
[37] N. Ikonen,et al. An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) in a secondary care hospital in Finland, May 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[38] A. Lansky,et al. Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine — United States, September 6, 2020–May 1, 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[39] Hannah R. Meredith,et al. Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios — United States, April–September 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[40] William L. Hamilton,et al. SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough , 2021 .
[41] Xiaoqian Jiang,et al. Factors Associated With COVID-19 Death in the United States: Cohort Study , 2021, JMIR public health and surveillance.
[42] A. Al-Zalabani,et al. Association of Viral Load in SARS-CoV-2 Patients With Age and Gender , 2021, Frontiers in Medicine.
[43] H. Schuitemaker,et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine , 2021, The New England journal of medicine.
[44] Aditya Sharma,et al. COVID-19 Infections Among Healthcare Personnel in the United States Veterans Health Administration, March - August, 2020. , 2020, Journal of occupational and environmental medicine.
[45] E. Walsh,et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.
[46] E. Petinaki,et al. Children and Adolescents With SARS-CoV-2 Infection , 2020, The Pediatric infectious disease journal.
[47] P. Shi,et al. In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age , 2020, PLoS biology.
[48] A. Charlett,et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[49] T. Heald-Sargent,et al. Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). , 2020, JAMA pediatrics.
[50] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[51] G. Biele,et al. An analysis of SARS-CoV-2 viral load by patient age , 2020, medRxiv.
[52] Anne Kimball,et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility , 2020, The New England journal of medicine.
[53] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[54] R. Irizarry. ggplot2 , 2019, Introduction to Data Science.
[55] E. Sciore. Strategies , 2018, Java Program Design.
[56] Hadley Wickham,et al. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .
[57] OUP accepted manuscript , 2021, International Journal Of Epidemiology.